Emrullah Yilmaz

17PUBLICATIONS
119CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 15, 2026
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.

|May 31, 2026
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

|May 13, 2026
Role of molecular driver mutations in recurrence of early-stage laryngeal cancer following narrow field definitive radiotherapy.

|May 08, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

|Apr 21, 2026
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

|Jun 19, 2025
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.

Timothy A Yap, Olivier Rixe, Capucine Baldini

Pageof 3

Frequent Collaborators

4 joint publications

Paul L Swiecicki

3 joint publications

Ari Joseph Rosenberg

3 joint publications

Mahadi Baig

2 joint publications

Trisha Michel Wise-Draper